4.2 Review

Behavioral medicine for migraine and medication overuse headache

期刊

CURRENT PAIN AND HEADACHE REPORTS
卷 13, 期 3, 页码 241-248

出版社

SPRINGER
DOI: 10.1007/s11916-009-0041-x

关键词

-

资金

  1. National Headache Foundation from Allergan Pharmaceuticals
  2. GlaxoSmithKline
  3. Merck
  4. Ortho-McNeil Neurologics Inc.
  5. Endo Pharmaceuticals

向作者/读者索取更多资源

Primary headaches, including migraine and medication overuse headache (MOH), can be conceptualized as biobehavioral disorders based on the interaction of biological, psychological, and environmental factors. This article reviews empirically supported and efficacious behavioral approaches to the treatment and management of headaches in general, with an emphasis on migraine and MOH from a biopsychosocial perspective. Evidence-based behavioral medicine treatments for migraine and MOH are reviewed, including patient education, cognitive behavioral therapy, and biobehavioral training (biofeedback, relaxation training, and stress management). Information regarding psychological comorbidities and risk factors for progression of migraine and the development of MOH is also reviewed. Strategies are provided for enhancing adherence and motivation, as well as facilitating medical communication.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据